Press Releases

The Phase 3 study compared abemaciclib in combination with an aromatase inhibitor versus an aromatase inhibitor alone in patients with HR+, HER2- advanced breast cancer INDIANAPOLIS, April 24, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating […]

Findings Presented at The International Liver Congress™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously Failed KENILWORTH, N.J. April 22, 2017 –(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) […]

Study Evaluated VA Population with High Incidence of Co-Morbidities KENILWORTH, N.J. April 21, 2017 –(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who were administered ZEPATIER® in the U.S. […]

INDIANAPOLIS, April 20, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place April 22-28, 2017, in Boston. Lilly will present four abstracts at AAN, including safety and patient outcomes data for […]

KENILWORTH, N.J. April 20, 2017 –(BUSINESS WIRE)–Merck, known as MSD outside the United States and Canada, announced today a $300,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF) in Africa. The donation will be offered to 10 NGOs beginning this year, and will be administered […]